Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas.

Journal of neuropathology and experimental neurology - 1 May 2015

Reis Gerald F, Pekmezci Melike, Hansen Helen M, Rice Terri, Marshall Roxanne E, Molinaro Annette M, Phillips Joanna J, Vogel Hannes, Wiencke John K, Wrensch Margaret R, Walsh Kyle M, Perry Arie

Abstract excerpt

Lower-grade (World Health Organization Grades II and III) gliomas vary widely in clinical behavior and are classified as astrocytic, oligodendroglial, or mixed. Anaplasia depends greatly on mitotic activity, with CDKN2A loss considered as the most common mechanism for cell cycle dysregulation. We investigated whether loss of the CDKN2A gene is associated with overall survival across pathologically and genetically...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Astrocytoma
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Brain Neoplasms

Share to Cyclin-Dependent Kinase Inhibitor p16

Share to Gene Expression Regulation, Neoplastic

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Survival Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 25853694
DOI: 10.1097/NEN.0000000000000188
PMCID: PMC4397174

Genes

ATRX

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas.PMID 25853694Read ↗

CDKN2A mutations have equivalent prognostic significance to homozygous deletion in IDH-mutant astrocytoma.Semantic proximity Read ↗

IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations.Semantic proximity Read ↗

Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma.Semantic proximity Read ↗

ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples samples.Semantic proximity Read ↗

Clinical Utility of Assessing CDKN2A Status in Recurrent AstrocytomasSemantic proximity Read ↗

Genetic profile of astrocytic and oligodendroglial gliomas.Semantic proximity Read ↗

CDKN2A/B Homozygous Deletions in Astrocytomas: A Literature ReviewSemantic proximity Read ↗

Prognostic value of DNA methylation subclassification, aneuploidy, and CDKN2A/B homozygous deletion in predicting clinical outcome of IDH mutant astrocytomas.Semantic proximity Read ↗

Molecular Classification Defines 4 Prognostically Distinct Glioma Groups Irrespective of Diagnosis and GradeSemantic proximity Read ↗

CDKN2A/B mutations and allele-specific alterations stratify survival outcomes in IDH-mutant astrocytomas.Semantic proximity Read ↗

Molecular markers related to patient outcome in patients with IDH-mutant astrocytomas grade 2 to 4: A systematic review.Semantic proximity Read ↗

Canonical amplifications and CDKN2A/B loss refine IDH1/2-mutant astrocytoma prognosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.